Ellison Medical Institute and UniQuest enter exclusive license to advance novel prostate cancer therapy toward first-in-human studies
· cision pr newswire
AI Briefing
- Ellison Medical Institute partners with UniQuest for QED-203, a novel prostate cancer therapy.
- QED-203 is for advanced and therapy-resistant prostate cancer treatment.
- UniQuest will commercialize the treatment, advancing it toward first-in-human studies.
Source Summary
LOS ANGELES, June 22, 2026 /PRNewswire/ -- The Ellison Medical Institute (EMI) has entered into an exclusive license with UniQuest, the commercialization company of The University of Queensland (UQ), to advance QED-203, a promising new treatment for advanced and therapy-resistant prostate...
Advertisement